SPOTLIGHT: FDA accepts BioDelivery drug app

The FDA has accepted BioDelivery Sciences International's new drug application for its nausea and vomiting treatment, Emezine. The FDA now has about nine months to decide whether to approve the product. If it receives the FDA's blessing, Emezine would be the BioDelivery's first drug to hit the market. The company licensed the drug from Reckitt Benckiser Healthcare. Report

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.